- Home
- BCRX
as 09-06-2024 4:00pm EST
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 1.6B | IPO Year: | 1994 |
| Target Price: | $14.17 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.03 - $8.88 | Next Earning Date: | 10-31-2024 |
| Revenue: | $382,236,000 | Revenue Growth: | 24.65% |
| Revenue Growth (this year): | 33.34% | Revenue Growth (next year): | 17.44% |
Stock Insider Trading Activity of BioCryst Pharmaceuticals Inc. (BCRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McKee Amy E | BCRX | Director | Jun 24 '24 | Sell | $6.32 | 8,600 | $54,352.00 | 27,831 | |
| SANDERS MACHELLE | BCRX | Director | Jun 17 '24 | Sell | $6.00 | 4,689 | $28,134.00 | 27,742 | |
| HEGGIE THERESA | BCRX | Director | Jun 12 '24 | Sell | $6.11 | 6,698 | $40,924.78 | 52,852 |
Latest BioCryst Pharmaceuticals Inc. News
BCRX Breaking Stock News: Dive into BCRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
GlobeNewswire
3 days ago
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
GlobeNewswire
4 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
10 days ago
High Growth Tech Stocks To Watch In August 2024
GlobeNewswire
17 days ago
BioCryst to Present at Upcoming Investor Conferences
Motley Fool
a month ago
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
Zacks
a month ago
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
Zacks
a month ago
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
Compare BCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCRX BioCryst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.